ReviewFrontiers in immunology2026
Immuno-metabolic crosstalk in osteoarthritis: from mechanisms to therapies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is a heterogeneous whole-joint disorder influenced by mechanical stress, aging, previous trauma, genetic susceptibility, subchonrral bone alterations, and localized inflamation.Emerging evidence suggests that immune and metabolic processes alterations may be involved in OA pathogenesis particularly in inflammatory and metabolically dysregulated subtypes. Content: This narrative review summarizes the bidirectional crosstalk between immune and metabolic processes during OA progression. Human observational studies and experimental models suggest that immune-cell activation and metabolic dysfunction may interact to influence synovial inflammation and cartilage homeostasis although their causal relevance and relative contributions vary across OA phenotypes. We further discuss emerging immunometabolic strategies targeting glycolytic and lipid-metabolic pathways as well as predominantly experimental approaches involving gene editing synthetic biology and stem cell-based therapies. Conclusion: Integrating multi-omics technologies with personalized medicine may improve patient stratification and dynamic monitoring and could facilitate the future development of more personalized and potentially disease-modifying strategies for OA.Future research should focus on clarifying the dynamic immunometabolic network underlying OA and promoting the clinical translation of innovative strategies through artificial intelligence and interdisciplinary collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.